Charles Rhyee
Stock Analyst at TD Cowen
(1.96)
# 3,145
Out of 5,113 analysts
68
Total ratings
42.22%
Success rate
-7.61%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IQV IQVIA Holdings | Maintains: Hold | $215 → $245 | $239.43 | +2.33% | 3 | Jan 22, 2026 | |
| ICLR ICON Public Limited Company | Maintains: Hold | $172 → $183 | $187.42 | -2.36% | 6 | Jan 22, 2026 | |
| FTRE Fortrea Holdings | Maintains: Hold | $7 → $15 | $17.06 | -12.08% | 4 | Jan 22, 2026 | |
| MDLN Medline | Initiates: Buy | $46 | $44.84 | +2.59% | 1 | Jan 12, 2026 | |
| GDRX GoodRx Holdings | Maintains: Buy | $7 → $6 | $2.52 | +138.10% | 8 | Nov 10, 2025 | |
| CRL Charles River Laboratories International | Maintains: Buy | $205 → $197 | $222.35 | -11.40% | 6 | Nov 10, 2025 | |
| COR Cencora | Maintains: Buy | $350 → $400 | $355.51 | +12.51% | 1 | Nov 10, 2025 | |
| CI The Cigna Group | Maintains: Buy | $387 → $333 | $280.41 | +18.75% | 1 | Nov 4, 2025 | |
| CVS CVS Health | Maintains: Buy | $99 → $100 | $83.87 | +19.23% | 1 | Nov 3, 2025 | |
| CAH Cardinal Health | Maintains: Buy | $183 → $225 | $210.93 | +6.67% | 3 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $27 | $36.21 | -25.43% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $356 → $462 | $602.34 | -23.30% | 6 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $297 → $380 | $224.18 | +69.51% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $830 → $864 | $826.62 | +4.52% | 4 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $9 → $8 | $6.29 | +27.19% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $4.06 | +23.15% | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $100 → $50 | $4.72 | +959.32% | 3 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $56 | $13.58 | +312.37% | 2 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $360 → $280 | $11.43 | +2,349.69% | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $3.71 | +1,247.71% | 2 | Jun 21, 2022 |
IQVIA Holdings
Jan 22, 2026
Maintains: Hold
Price Target: $215 → $245
Current: $239.43
Upside: +2.33%
ICON Public Limited Company
Jan 22, 2026
Maintains: Hold
Price Target: $172 → $183
Current: $187.42
Upside: -2.36%
Fortrea Holdings
Jan 22, 2026
Maintains: Hold
Price Target: $7 → $15
Current: $17.06
Upside: -12.08%
Medline
Jan 12, 2026
Initiates: Buy
Price Target: $46
Current: $44.84
Upside: +2.59%
GoodRx Holdings
Nov 10, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.52
Upside: +138.10%
Charles River Laboratories International
Nov 10, 2025
Maintains: Buy
Price Target: $205 → $197
Current: $222.35
Upside: -11.40%
Cencora
Nov 10, 2025
Maintains: Buy
Price Target: $350 → $400
Current: $355.51
Upside: +12.51%
The Cigna Group
Nov 4, 2025
Maintains: Buy
Price Target: $387 → $333
Current: $280.41
Upside: +18.75%
CVS Health
Nov 3, 2025
Maintains: Buy
Price Target: $99 → $100
Current: $83.87
Upside: +19.23%
Cardinal Health
Nov 3, 2025
Maintains: Buy
Price Target: $183 → $225
Current: $210.93
Upside: +6.67%
Nov 3, 2025
Maintains: Hold
Price Target: $30 → $27
Current: $36.21
Upside: -25.43%
Oct 24, 2025
Maintains: Sell
Price Target: $356 → $462
Current: $602.34
Upside: -23.30%
Oct 7, 2025
Upgrades: Buy
Price Target: $297 → $380
Current: $224.18
Upside: +69.51%
Sep 24, 2025
Maintains: Buy
Price Target: $830 → $864
Current: $826.62
Upside: +4.52%
Oct 31, 2024
Maintains: Hold
Price Target: $9 → $8
Current: $6.29
Upside: +27.19%
May 3, 2023
Maintains: Outperform
Price Target: $4 → $5
Current: $4.06
Upside: +23.15%
Mar 23, 2023
Downgrades: Market Perform
Price Target: $100 → $50
Current: $4.72
Upside: +959.32%
Oct 20, 2022
Maintains: Outperform
Price Target: $70 → $56
Current: $13.58
Upside: +312.37%
Aug 16, 2022
Maintains: Outperform
Price Target: $360 → $280
Current: $11.43
Upside: +2,349.69%
Jun 21, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $3.71
Upside: +1,247.71%